Cramer’s week ahead: Expect more volatility as tech earnings, midterms loom
Context:
Stocks faced renewed volatility as AI optimism cooled heading into a busy week of earnings and midterm elections. After a brief tech-led rally, major indices retraced with the Nasdaq, S&P 500, and Dow all finishing lower on Friday, signaling that the near-term rally may stall amid uncertainty about policy, data-center spending, and key reports. Cramer advised investors not to chase a bottom in the Nasdaq and to favor high-quality names that appear beaten down, while highlighting Apple’s valuation and upcoming earnings as a critical test. The week ahead centers on Apple, AMD, Pfizer, Amgen, CVS, McDonald’s, Kimberly-Clark, and the monthly jobs report, with data-center regulation and AI spending shaping the backdrop. Outlook remains cautious, as earnings momentum and macro signals could determine how risk appetite evolves into year-end.
Dive Deeper:
Theweek opened with a broad equity rally driven by AI optimism, but equities gave back most gains by Friday, leaving major averages down on the close.
Jim Cramer warned that volatility could persist due to the upcoming midterm elections, overseas uncertainty, a jobs report, and a slate of earnings reports that could redefine market sentiment.
Apple is due to report after the bell, with the stock trading near record highs but valuation near 40 times earnings, creating a narrow margin for disappointment.
Palantir is anticipated to post encouraging results, bolstered by strong feedback on the value of its AI software, reinforcing the AI leadership narrative.
Data-center development could be pressured by political opposition in some states, potentially impacting AI infrastructure spending for tech and cloud developers.
AMD is expected to outperform Intel in the semiconductor results, serving as a key test for the sector after Intel’s weaker showing.
Other earnings highlights include Pfizer, Amgen, CVS Health, McDonald’s, and Kimberly-Clark, with expectations ranging from pharmaceutical earnings upside to concerns about CVS’s pharmacy benefit management moat.